Description
Jason T. Jacobson, MD, FHRS, is joined by guests Laurent Macle, MD, FHRS, and Peter M. Kistler, MBBS, PhD, FHRS, for a discussion of the Improved PAF Trial. Prior studies have demonstrated clinical benefits associated with cryoballoon pulmonary vein isolation (PVI) and concomitant posterior wall isolation (PWI) in patients with persistent atrial fibrillation (AF). However, the role for this approach in patients with paroxysmal atrial fibrillation (PAF) remains unclear. Compared with cryoballoon PVI, cryoballoon PVI+PWI appears to be associated with greater freedom from recurrent atrial arrhythmias and AF in patients with PAF during long-term follow-up >3 years.
Learning Objectives
- This study investigated the acute and long-term outcomes of PVI vs PVI+PWI using cryoballoon in patients with symptomatic PAF.
Article Authors and Podcast Contributors
Article Authors
Arash Aryana, Anna M. Thiemann, Deep K. Pujara, Laura L. Cossette, Shelley L. Allen, Mark R. Bowers, Maheer Gandhavadi, Russell Heath, Amar D. Trivedi, Padraig Gearoid O’Neill, Ethan R. Ellis, and André d’Avila
Podcast Contributors
Jason T. Jacobson, MD, FHRS, of Westchester Med Center-New York Med College
Laurent Macle, MD, FHRS, of Montreal Heart Institute
Peter M. Kistler, MBBS, PhD, FHRS, of The Alfred Hospital Heart Center
Disclosures
All relevant financial relationships have been mitigated.
Host Disclosure(s):
J. Jacobson: Honoraria/Speaking/Consulting Fee: American College of Cardiology, Zoll Medical Corporation; Research (Contracted Grants for PIs Named Investigators Only): Aboot, Phillips; Stocks (Privately Held): Atlas 5D
Contributor Disclosure(s):
L. Macle: Honoraria/Speaking/Consulting Fee: Biosense Webster, Inc., Abbott Medical, Bristol-Myers Squibb, Servier, Medtronic Inc., Pfizer, Inc.
P. Kistler: Honoraria/Speaking/Consulting Fee: Abbott/Abbott Medical
Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):
J. Glenn: No relevant financial relationships with ineligible companies to disclose.
S. Sailor: No relevant financial relationships with ineligible companies to disclose.